Palatin Technologies Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
Palatin Technologies Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for MELODY-1 in Oral MC4R Agonist PL7737 in Animal Model of Obesity (Phase 3) using Small Molecule.
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| PL7737 | Oral MC4R Agonist PL7737 in Animal Model of Obesity | Small Molecule | Preclinical | Public pipeline row |
| GLP-1 | n/a | n/a | Phase 2 | Public pipeline row |
| PL7737 Oral Small Molecule MC4R Agonist | n/a | Peptide | Phase 1 | Public pipeline row |
| MELODY-1 | n/a | n/a | Phase 3 | Public pipeline row |
| PL8177 Oral MC1R Agonist | n/a | n/a | Phase 2 | Public pipeline row |
| MCR Agonist | n/a | n/a | Phase 2 | Public pipeline row |
| PL9643 | n/a | n/a | Phase 3 | Public pipeline row |
| PL8177 | n/a | n/a | Phase 1 | Public pipeline row |
No public catalyst rows matched this view yet.
Estimated cash runway: Runway > 12 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT00425256 | Phase 2 | COMPLETED | n/a | 2007-05 |
| NCT00686803 | Phase 2 | COMPLETED | 21 | 2008-07 |
| NCT01382719 | Phase 2 | COMPLETED | 612 | 2012-09 |
| NCT02333071 | Phase 3 | COMPLETED | 723 | 2016-07 |
| NCT02338960 | Phase 3 | COMPLETED | 714 | 2016-08 |
| NCT04268069 | Phase 2 | COMPLETED | 160 | 2020-10-05 |
| NCT05201170 | Phase 3 | COMPLETED | 575 | 2023-09-01 |
| NCT04318145 | Phase 2 | TERMINATED | 15 | 2023-12-08 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.